How do I account for an R&D tax relief claim in my company's accounts?

Two separate accounting questions

It’s easy to conflate “how do I account for my R&D costs” with “how do I account for my R&D tax credit,” but they’re governed by different parts of your accounting framework and, for the second question, by different parts of the tax legislation depending on which scheme you’re claiming under. Get the underlying expenditure right first — how you’ve accounted for the spend affects what your auditor or accountant expects to see, though it doesn’t itself determine what’s qualifying expenditure for R&D tax purposes, which is a separate test covered in What costs qualify for R&D tax relief?.

How the underlying R&D spend is treated

What your accounting framework requires depends on which one you report under:

• FRS 105 (the micro-entities standard) requires all R&D expenditure to be written off as incurred. There is no option to capitalise any of it as an intangible asset, regardless of how it would be treated under FRS 102 or IAS 38.
• FRS 102 Section 18 distinguishes a research phase from a development phase. Research expenditure must be expensed as incurred. Development expenditure may be capitalised as an intangible asset if specific recognition criteria are met — this is a policy choice, not a requirement, and where research and development can’t be distinguished from each other, the whole of it is treated as research and written off.
• IAS 38 draws the same research/development distinction, but development expenditure that meets the recognition criteria must be capitalised — there is no accounting policy choice under IFRS the way there is under FRS 102.

A specific point worth knowing if a company changes accounting framework. Where R&D expenditure that was previously written off gets capitalised as an intangible asset on adopting IAS, FRS 101 or FRS 102 for the first time, the resulting uplift to the balance sheet is exempt from tax, and no amortisation deduction is available against it going forward. This sits outside the R&D tax relief rules entirely — it’s a general intangible fixed assets transitional rule, not something specific to a claim.

None of this changes what counts as qualifying expenditure for the R&D claim itself. A cost can be capitalised in the accounts and still be qualifying revenue expenditure for R&D tax purposes — the two tests are different, and conflating them is a common source of confusion at the cost-gathering stage.

Whether the relief itself is taxable income

This is the question that actually drives where the relief appears in your accounts, and it has a firm statutory answer that differs by scheme.

The merged scheme’s R&D expenditure credit is a taxable receipt, by direct statutory requirement. If your company is entitled to and claims the credit, you must bring the amount of the credit into account as a receipt in calculating your trading profits for corporation tax purposes. This is what makes the credit “above the line” — it increases pre-tax profit before the tax charge on it is calculated, exactly like the legacy RDEC scheme it replaced for accounting periods beginning on or after 1 April 2024.

The SME scheme and ERIS payable tax credit is not taxable income of the company. There is no equivalent statutory provision bringing it into account as a receipt — the credit is paid as a direct reduction of your tax position, not as income you’re then taxed on. This is what makes it “below the line”: it never touches pre-tax profit, it only affects the tax line.

The mechanics of what this means for your profit and loss account layout, and how to compute the notional tax deduction that keeps profit-making and loss-making claimants on a comparable footing, are covered in Where does the R&D credit sit in my profit and loss account?.

When to recognise the credit in your accounts

There is no R&D-specific accounting standard telling you when to recognise the relief. It falls to be recognised under the same general current tax principles that apply to any other tax position — Section 29 of FRS 102 for UK GAAP reporters, or IAS 12 for IFRS reporters — not under the government grants standard, even though the relief is, in substance, government support for R&D activity. The reason it isn’t treated as a grant is that it’s delivered entirely through the tax system, against entitlement conditions set out in tax legislation, rather than through a separate grant-award mechanism with its own conditions to satisfy.

In practice, this means the credit is normally accrued in the accounting period the qualifying R&D expenditure was actually incurred, at a reasonable estimate of what the claim will be worth — not deferred until the claim is submitted to HMRC, and not deferred until HMRC has agreed it. The entitlement arises from applying already-enacted legislation to expenditure that has already happened; it isn’t contingent on a future event in the way a discretionary grant award might be. Where the final, filed figure differs from the year-end estimate — because costs were refined, or the relevant-projects selection changed, or the claim was reduced during a compliance check — that’s a true-up in the following period’s accounts, not evidence the earlier accrual was wrong in principle.

Genuine estimation uncertainty is a different matter from recognition timing, and needs separate judgement. Where a claim includes a project you know is contestable — marginal on the uncertainty test, or in an area HMRC has recently scrutinised heavily — that’s a reason to reflect the risk in the size of the accrual, or to disclose the uncertainty, not a reason to delay recognising the claim at all. FRS 102’s Section 29 was amended as part of the 2024 periodic review to introduce explicit requirements on measuring current tax where its amount is uncertain, for accounting periods beginning on or after 1 January 2026 — worth checking directly once in effect, since it bears squarely on exactly this judgement for any claim carrying real enquiry risk.

Presentation and disclosure

Where the credit is taxable (merged scheme), it’s typically shown as other operating income, with the resulting tax charge on it forming part of the normal tax line — the credit and its own tax cost are shown gross of each other, not netted off. Where the credit isn’t taxable (SME scheme, ERIS), it’s shown entirely within the tax line, usually as a reduction of the current tax charge or, for a company with no corporation tax liability to reduce, as a tax credit in its own right.

Either way, the accounting policy note should say which scheme the claim is made under and how the credit has been recognised, and — given the estimation judgement above — whether the figure in the accounts is the amount actually claimed or a year-end estimate pending completion of the claim.

If HMRC later changes the claim

A reduction agreed or imposed after the accounts for the claim year have already been finalised is a prior-period matter, not something that reopens the year the accrual was first made — see What is a volume compliance check on my R&D claim? and Can HMRC reopen my R&D claim after the enquiry window has closed? for how and when that can happen. Whether it’s treated as a correction of an accounting estimate or as a prior-period error depends on the facts — an estimate that turns out to have been reasonable at the time but is refined by new information is different from a claim that was wrong when it was made — and that distinction is for your accountant or auditor to make on the specific facts, not something this entry can settle in the abstract.